The genetic basis of human tumor progression was studied by examining two hematopoietic disorders, chronic myelogenous leukemia (CML), and myelodysplasia (MDS). These diseases are characterized by a preleukemic or premalignant phase which progresses to acute leukemia. Using a sensitive tumorigenicity assay, point mutations in the ras protooncogenes were identified in the earliest preleukemic stage of MDS, but in the late or acute leukemic phase of CML. Furthermore, in MDS, the presence of aberrant ras alleles predicted for subsequent progression to acute leukemia. These data suggest that mutant ras genes are important factors in leukemogenesis, but that these mutant ras alleles have different progression functions depending on the disease context. Underscoring the complexity of the progression process, a novel transforming gene (gene X) was identified in the blood cells from two patients with CML. In light of these data, a study of ras mutations in preleukemic states is proposed using a sensitive method for detecting point mutations in small quantities of DNA: polymerase chain reaction. In this fashion, will extend our initial findings in a large number of patients and will determine the clinical significance of these findings. Blood cells will be separated into lineage specific fractions (i.e. granulocytes, monocytes, and lymphocytes) and the stem cell which sustained the mutation in ras can be identified. Lastly, gene X will be cloned from a secondary nude mouse transformant using cosmid vectors. Once cloned, the critical genetic lesion(s) which converted the normal cellular homologue of gene X into its transforming counterpart can be determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA049240-02
Application #
3193276
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1989-01-01
Project End
1991-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
2
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Guttridge, Katherine L; Luft, J Christopher; Dawson, Thomas L et al. (2002) Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem 277:24057-66
Burchert, A; Attar, E C; McCloskey, P et al. (1998) Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene 16:3177-87
Fridell, Y W; Villa Jr, J; Attar, E C et al. (1998) GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273:7123-6
Fridell, Y W; Jin, Y; Quilliam, L A et al. (1996) Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 16:135-45
O'Bryan, J P; Fridell, Y W; Koski, R et al. (1995) The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 270:551-7
Neubauer, A; Dodge, R K; George, S L et al. (1994) Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603-11
Neubauer, A; Greenberg, P; Negrin, R et al. (1994) Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8:638-41
Neubauer, A; Fiebeler, A; Graham, D K et al. (1994) Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84:1931-41
McCloskey, P; Pierce, J; Koski, R A et al. (1994) Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ 5:1105-17
Neubauer, A; He, M; Schmidt, C A et al. (1993) Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 7:593-600

Showing the most recent 10 out of 19 publications